CHEMM ChemoMetec

Guidance for the 2023/24 financial year

Guidance for the 2023/24 financial year

ANNOUNCEMENT NO. 242

13 September 2023



Guidance for the 2023/24 financial year

ChemoMetec has today approved the annual report for 2022/23, including the guidance for 2023/24, which is considered inside information.

For 2023/24, ChemoMetec expects revenue in the range of DKK 400-435 million (2022/23: DKK 442.3 million) and EBITDA in the range of DKK 200-220 (2022/23: DKK 251.0 million).

The annual report for 2022/23, which is released along with this announcement, sets out the underlying assumptions applied in the preparation of the guidance for 2023/24.



Additional information

Rasmus Kofoed, CEO

Tel.: (+45) 26 72 68 19        

Niels Høy Nielsen, CFO

Tel.: (+45) 25 51 87 24        



About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements.

ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to .



EN
13/09/2023

Underlying

CHEMMChemoMetec

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ChemoMetec

 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Indberetning af ledende medarbejderes transaktioner

Indberetning af ledende medarbejderes transaktioner MEDDELELSE NR. 301                 9. februar 2026 Indberetning af ledende medarbejderes transaktioner ChemoMetec A/S har i henhold til artikel 19 i forordning (EU) nr. 596/2014 modtaget nedenstående indberetning om transaktioner i ChemoMetec A/S aktier udført af personer med ledelsesansvar og/eller personer, der er nært knyttet til dem. Se indberetning af bestyrelsesformand Niels Thestrups transaktioner i vedhæftede pdf-dokument. Yderligere oplysninger kan fås ved henvendelse til: Kim Nicolajsen, CFOTelefon: (+45) 48 13 10 20      ...

February 9, 2026 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Notification of managers’ transactions

Notification of managers’ transactions ANNOUNCEMENT NO. 301 9 February 2026 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of the Chair of ChemoMetec’s Board of Directors Niels Thestrup in the attached PDF document. For further information, please contact: Kim Nicolajsen, CFOTelephone (+45) 48 13 10...

February 9, 2026 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

ChemoMetec enters Letter of Intent with Roche Diagnostics

ChemoMetec enters Letter of Intent with Roche Diagnostics ANNOUNCEMENT NO. 300 – IN ENGLISH ONLY 4 February 2026 ChemoMetec enters Letter of Intent with Roche Diagnostics ChemoMetec has entered a Letter of Intent with Roche Diagnostics aiming to pursue a collaboration with the goal of creating synergies between the parties’ technologies in the field of bioprocess monitoring. Over the course of 2026 the parties intend to explore and solidify initial ideas of combining the parties’ technologies into validated solutions in the field of bioprocess monitoring, starting with developing a co...

February 4, 2026 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

ChemoMetec enters Letter of Intent with Roche Diagnostics

ChemoMetec enters Letter of Intent with Roche Diagnostics ANNOUNCEMENT NO. 300 4 February 2026 ChemoMetec enters Letter of Intent with Roche Diagnostics ChemoMetec has entered a Letter of Intent with Roche Diagnostics aiming to pursue a collaboration with the goal of creating synergies between the parties’ technologies in the field of bioprocess monitoring. Over the course of 2026 the parties intend to explore and solidify initial ideas of combining the parties’ technologies into validated solutions in the field of bioprocess monitoring, starting with developing a connectivity of Chem...

February 4, 2026 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Interim report 2025/26 - Organic growth despite challenges in the Nort...

Interim report 2025/26 - Organic growth despite challenges in the North American market ANNOUNCEMENT NO. 299 4 February 2026 Interim report for the first half of 2025/26         Organic growth despite challenges in the North American market Martin Helbo Behrens, CEO: In the first half of 2025/26, our revenue was up 3% measured in local currencies, while in Danish kroner it was down to DKK 249.0 million, a year-on-year decrease of 1%. Despite this, EBITDA and the EBITDA margin showed a slight increase. Revenue was affected by a sharp slowdown in US demand, as many of our customers in t...

February 4, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch